Antimicrobial resistance (AMR) is a serious public health threat in both developed and
developing countries. Many developing countries, including Rwanda, lack adequate …

Background Limited treatment data are available for hepatitis C virus (HCV) in sub-Saharan
Africa, especially for genotype 4. Our objective was to establish the safety and efficacy of …

Aim Evidence to show whether lifestyle intervention programs are beneficial for patients with
diabetes in resource-limited countries is lacking. The present study assessed the additional …

Background Successful H. pylori treatment requires the knowledge of local antimicrobial
resistance. Data on the efficacy of H. pylori eradication regimens available in sub-Saharan …

Abstract Background Direct-acting antivirals (DAAs) are becoming accessible in sub-
Saharan Africa. This study examined the effectiveness of DAAs in patients treated through …

Background Strongyloides stercoralis is one of the most neglected tropical diseases.
Sparse, dated central African and Rwandan data on seroprevalence are available to guide …

Introduction Dyspepsia accounts for a significant burden of worldwide disease, but there is a
relative paucity of data from the sub-Saharan African setting. We undertook to describe the …

Around 71 million people are living with chronic hepatitis C virus (HCV) infection, with
approximately 14% residing in sub‐Saharan Africa. Direct‐acting antiviral (DAA) therapies …

• In Rwanda, Viral Hepatitis seroprevalence is estimated at 3.1% to 4.1% within the general
population and between 4.5% to 4.7 Page 1 ILC2019 Poster presented at: • In Rwanda, Viral …

Background: Inhabitants from malaria endemic zones often present with enlarged spleen,
mainly due to hyper reactive malarial splenomegaly (HMS), and it is seen more commonly …